drugset / Trial / NCT00886977
Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS)
NaSingle-groupOpen-labelTreatment
Summary
The efficacy and safety are evaluated when YAM80 is administered orally to the patients of Amyotrophic Lateral Sclerosis (ALS).
Timeline
- Start
- 2009-04
- Primary completion
- 2010-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YAM80 | Unknown | 2 mg | Oral |
| Subject | YAM80 | Unknown | 6 mg | Oral |